RxDoctor Payments Data

Enrique Urrea Mendoza, MD

Neurology · Tallahassee, FLNPI 1578346243

Payments from drug & device makers

$6,343in general payments, 2019–2025

Across 53 payments — averaging $119.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Medtronic$365
  • MDD US Operations, LLC$118
  • AbbVie$91
  • Argenx US, Inc.$70
  • Acadia Pharmaceuticals Inc$58
  • plus $229 from 6 others

What the payments were for

  • Travel & lodging$4,40369%
  • Food & beverage$1,94031%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,343 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$45,407
Medicare patients
135
Services billed
588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$87,223
NeuproRotigotine28$18,232
Carbidopa-LevodopaCarbidopa/Levodopa278$14,871
AmantadineAmantadine Hcl36$3,490
Primidone59$3,346
Rivastigmine17$3,340
Carbidopa-Levodopa ErCarbidopa/Levodopa101$2,442
Entacapone11$2,224
RivastigmineRivastigmine Tartrate24$1,778
Ropinirole Hcl31$986
Memantine Hcl28$489
Quetiapine Fumarate23$333
Donepezil Hcl14$171
Clonazepam11$101
Pramipexole DihydrochloridePramipexole Di-Hcl14$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$29$87,22311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.

Other neurology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →